Stockwinners Market Radar for June 13, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:09 EDT Cathie Wood's ARK Investment bought 270.7K shares of Teradyne today

19:01 EDT Synopsys to collaborate with Samsung across Foundry processes - Synopsys (SNPS) announced an expanded agreement with Samsung (SSNLF) Foundry to develop a broad portfolio of IP to reduce design risk and accelerate silicon success for automotive, mobile, high-performance computing and multi-die designs. This agreement expands Synopsys' collaboration with Samsung to enhance the Synopsys IP offering for Samsung's advanced 8LPU, SF5, SF4 and SF3 processes and includes Foundation IP, USB, PCI Express, 112G Ethernet, UCIe, LPDDR, DDR, MIPI and more. In addition, Synopsys will optimize IP for Samsung's SF5A and SF4A automotive process nodes to meet stringent Grade 1 or Grade 2 temperature and AEC-Q100 reliability requirements, enabling automotive chip designers to reduce their design effort and accelerate AEC-Q100 qualification. The auto-grade IP for ADAS SoCs will include design failure mode and effect analysis reports that can save months of development effort for automotive SoC applications.

18:13 EDT Gartner CEO sells $3.82M in common stock - In a regulatory filing, Gartner disclosed that its CEO Eugene Hlal sold 11K shares of common stock on June 9th in total transaction size of $3.82M.

17:51 EDT Toyota to continue to pursue 'multi-pathway approach' to electrification - Toyota announced a variety of new technologies that will support its transformation into a mobility company. Hiroki Nakajima, Executive Vice President and Chief Technology Officer, explained Toyota's technology strategy and the direction of future car manufacturing at a technical briefing session. In addition, he spoke on specific and diverse technologies, including concepts under development, which will help achieve the vision and policies that have been communicated so far. Also speaking were Takero Kato, who has been appointed president of the newly established BEV Factory, and Mitsumasa Yamagata, who is scheduled to be appointed president of the Hydrogen Factory to be launched in July. They elaborated on their respective strategies for the battery EV and hydrogen businesses. "In the area of electrification, we will continue to pursue a "multi-pathway approach," including the introduction of optimal powertrains for each region," Nakajima said. "In the area of intelligence, in addition to vehicles and services, we will also promote initiatives to expand our connection with society, such as Woven City. We will also continue to diversify our business by expanding our scope from "cars" to "society" to include freedom of mobility and diverse energy options for all. To promote these three themes technologically, we have been shifting resources to Advanced Development fields and actively investing in future-oriented areas since 2016, when the company system was inaugurated. As of March 2023, we have shifted more than half of our R&D staff and approximately half of our R&D expenses to Advanced Development fields while increasing the total amount. We will further accelerate this trend in the future." Reference Link

17:36 EDT Altisource Asset Management announces favorable ruling - Altisource Asset Management announced that the Supreme Court of the State of New York, Appellate Division, First Judicial Department issued a ruling in favor of the company that it did not breach any contractual obligation to redeem preferred shares held by Luxor Capital Group. The appellate court held that AAMC, "established its entitlement to summary judgment dismissing the complaint. In opposition failed to raise a triable issue of fact, and also failed to establish their entitlement to summary judgment on their own motion." The court further directed the Clerk to enter judgment dismissing Luxor's complaint.

17:31 EDT DoorDash CFO Inukonda sells over $245K in shares - The CFO of DoorDash Ravi Inukonda disclosed that he had sold 3,500 shares of company stock at $70.23 per share on June 9 for a total transaction amount of $245,805.

17:22 EDT Elastic CTO sells $21.2M in common stock as part of option expiry - In a regulatory filing, Elastic disclosed that its CTO Shay Banon sold 302K shares of common stock on June 9th in a total transaction size of $21.2M as part of option expiry.

17:13 EDT Fifth Third sees Q2 revenue down 2%-3% from Q1 - In a regulatory 8-K filing, the company also guides Q2 net interest income down 4%-5%, which "assumes the Fed funds remains the same through end of quarter".

17:08 EDT Archer Aviation shareholder Adcock sells $7M in company shares - Beneficial owner of Archer Aviation Brett Adcock disclosed the sale of 2,000,000 shares of stock between June 9 and June 12 at $3.49 per share for a total amount of $6,987,200.

17:01 EDT Copa Holdings reports May traffic up 15.8% from last year - For the month of May 2023, Copa Holdings' capacity, ASMs, increased 15.3%, while system-wide passenger traffic, RPMs, increased 15.8%, compared to 2022. As a result, system load factor for the month was 86.1%, 0.4 percentage points higher than May 2022.

16:54 EDT Catalent regains compliance with NYSE continued listing standards - Catalent announced that the company has received written notification from the New York Stock Exchange that it has officially regained compliance with the NYSE continued listing standards.

16:51 EDT Norwegian Cruise Line CEO sells $5.53M in common stock - In a regulatory filing, Norwegian Cruise Line disclosed that its CEO Frank Del Rio sold 300K shares of common stock on June 12th in a total transaction size of $5.53M.

16:37 EDT Cboe Global Markets announces five new senior executive hires - Cboe Global Markets announced five new senior executive hires that will continue to support the company's global expansion and drive its future growth and success. These appointments include Megan Goett as Senior Vice President, Chief Marketing Officer; Hatice Unal as Senior Vice President, Infrastructure; Laura Fuson as Vice President, Futures; Jodie Gunzberg as Head of Strategic Partnerships; and Katherine Kirkpatrick as Chief Legal Officer, Cboe Digital. The five senior leader appointments are as follows: Megan Goett joined as Senior Vice President, Chief Marketing Officer and is responsible for leading Cboe's global branding and marketing strategy. Goett has led a distinguished 20-year career in the financial services industry, executing global marketing campaigns and holding several senior leadership roles. Hatice Unal joined as Senior Vice President, Infrastructure and oversees the daily management of Cboe's infrastructure groups and components. Unal brings over 20 years of electronic trading technology experience and has held several technology leadership and strategy roles. Laura Fuson joined as Vice President, Futures and oversees the day-to-day operations of Cboe's futures business and identifies areas for growth in product development and distribution, including in the digital asset space. Fuson joins Cboe from SG Americas Securities, where she served as Director, Prime Services and Clearing, Platform Sales. Jodie Gunzberg joined as Head of Strategic Partnerships and leads partnerships and critical commercial relationships for Cboe including commercial arrangements with index providers, intellectual property owners and others. Katherine Kirkpatrick joined as Chief Legal Officer of Cboe Digital and oversees the legal support of Cboe Digital's trading and clearing venues. Prior, she served as General Counsel at Maple Finance and was formerly a partner at the global law firm King & Spalding, where she co-chaired both the Financial Services and Fintech, Blockchain, and Cryptocurrency groups.

16:34 EDT Eastside Distilling reaffirms Q2 positive EBITDA guidance - The Company reconfirmed its Q2 of positive EBITDA for its Craft division with a substantial reduction in the net operating loss for the division. Craft's operating performance continues to improve, with May posting the highest monthly segment sales ever. The Company has digitally printed more than 15 million cans since its new Portland, Oregon location was opened last year. The Company is also updating Q2 guidance to state that its Spirits division is performing better than internal profit plans.

16:32 EDT Eastside Distilling signs non-binding term sheet to convert debt for equity - Eastside Distilling announces it has signed a non-binding term sheet with key first and second lien debt holders that, if completed, will convert a substantial portion of outstanding debt to equity. This would significantly reduce interest expense going forward and help the Company to regain compliance with the Shareholders Equity Rule for continued Nasdaq listing. In the proposed transaction, principal creditors would exchange $6.2M of debt for equity at an exchange rate of no less than $4.00 per common share equivalent and no more than $4.80 per common share equivalent. New equity would be limited to less than 20% of total voting stock with the balance in new non-voting convertible preferred stock. In addition, interest payments on the remaining debt would be restructured and certain debt maturities would be extended. These changes would have a materially positive impact on cash flow and support the Company's growth initiatives, especially in digital can printing. After submitting the proposed deleveraging plan to Nasdaq, the Company received notification on June 8 that Nasdaq has extended the deadline for the Company to achieve compliance with its Shareholders Equity Rule to September 30. The Company received notice on May 30 that it had regained compliance with the minimum price requirement for continued listing.

16:32 EDT First Horizon to be added to BKX on June 20 - First Horizon (FHN) announced that, effective prior to the opening of business on Tuesday, June 20, the company will be added to the KBW Nasdaq Bank Index as part of index rebalancing for the second quarter of 2023. First Horizon was historically part of the BKX and was removed in the third quarter 2022 rebalance due the pending acquisition by Toronto-Dominion Bank (TD) which was subsequently terminated on May 4.

16:24 EDT The Bancorp, Chime extend partnership - The Bancorp announced that it has entered into a long-term extension of its private label banking services agreement with Chime Financial, Inc., a consumer fintech company. This renewed relationship further strengthens The Bancorp's position as the leader in delivering banking sponsorship services to the U.S. challenger banking sector. The renewed agreement between the two organizations ensures The Bancorp will maintain its key role as a banking partner and continue to hold Chime member deposit accounts. The partnership will enable Chime to continue to focus on designing innovative, easy-to-use, FDIC-insured banking services for everyday people. "We are thrilled to not only renew, but to also expand our partnership with Chime, as it solidifies our dedication to driving the future of fintech," said Ryan Harris, EVP and Head of Fintech Solutions at The Bancorp. "At The Bancorp, we are committed to embracing innovation and redefining what is possible in the world of banking. Our goal is to not only meet but exceed the needs and expectations of Chime members now and into the future," he concluded.

16:22 EDT Apollo Global announces structured equity investment in ITT, no terms - Apollo announced that funds managed by Apollo affiliates have agreed to make a structured equity investment in Intermodal Tank Transport , a leading global provider of ISO tank transportation logistics and depot services for bulk-liquid chemical and food-grade products. ITT will continue to be led by President and Chief Executive Officer Jon Hulsey and the existing management team. Financial terms were not disclosed. Founded in 1993, Intermodal Tank Transport is a recognized leader in ISO tank container transportation and logistics, serving hundreds of customers via its leading tank fleet and depot locations. ITT serves an essential role in the transportation value chain, arranging end-to-end logistics of bulk liquids for blue-chip customers across all major modes of transportation.

16:22 EDT HubSpot CEO Rangan sells 10,846 common shares - In a regulatory filing, HubSpot president and CEO Yamini Rangan disclosed the sale of 10,846 common shares of the company on June 12 at a price of $516.83 per share.

16:11 EDT Logitech CEO Bracken Darrell to leave company, Guy Gecht named interim CEO - Logitech International announced that Bracken Darrell, president and chief executive officer, will be departing the Company to pursue another opportunity. Darrell's resignation as president, CEO, and as a member of Logitech's board of directors is effective today, but he will remain with the company over the coming month to ensure a seamless transition. In line with the board's established succession planning process, board member Guy Gecht will step into the role of interim CEO while a global search of internal and external candidates is conducted. "As an experienced CEO, and member of Logitech's board since 2019, Guy has a deep understanding of Logitech and its strategy, and is well-placed as interim CEO to oversee the continued execution of the company's strategy," said Wendy Becker, Logitech's chairperson of the board. "We thank Bracken for his leadership during an exciting era of transformation at Logitech. Over his ten years as CEO, Bracken oversaw a period of consistent growth and helped to transform Logitech into an award-winning design company known for its unparalleled product innovation. We wish him well in the future and look forward to identifying his successor."

16:10 EDT Zuora names Pete Hirsch chief product and technology officer - Zuora announced the appointment of Pete Hirsch as its Chief Product and Technology Officer. Hirsch will join Zuora on July 10, 2023 and report to founder and CEO Tien Tzuo to lead the company's global product innovation and engineering functions. Hirsch comes to Zuora with more than 30 years of software engineering experience leading enterprise product and engineering organizations. Most recently, he was Chief Technology Officer at BlackLine, a financial controls and automation software company, where he led the company's product and technology groups, set its technology direction and scaled its global cloud platform. Prior to BlackLine, Hirsch was Executive Vice President of Technology and Operations at fintech provider Ellie Mae, where he oversaw all technology functions, including product development, public cloud and SaaS operations. "Pete is the right leader to further accelerate our product innovation engine and help companies make the critical shift to customer-centric business models," said Tzuo. "His proven ability to scale organizations across financial and accounting technology will be essential as we continue to expand our product suite. Pete is a compassionate and transparent leader who builds great cross-functional partnerships that align with our Zuora values."

16:09 EDT Acadia announces Phase 3 development candidate ACP-101 for PWS - Acadia Pharmaceuticals announced the addition of a new Phase 3 development candidate to its rare disease portfolio, ACP-101, for the treatment of hyperphagia in Prader-Willi syndrome. Acadia acquired worldwide rights to develop and commercialize ACP-101 with the acquisition of Levo Therapeutics in June 2022. "Acadia's acquisition of ACP-101 demonstrates our commitment to acquiring and developing novel drug candidates that address significant unmet needs in central nervous system disorders. The addition of this drug candidate to our rare disease portfolio is an important next step in the execution of our business development strategy," said Steve Davis, Acadia's President and Chief Executive Officer. "Prader-Willi syndrome is a rare genetic disorder with no approved treatments, characterized by life-threatening hyperphagia, in addition to a broad range of severe metabolic issues and behavioral challenges. We look forward to working with the Prader-Willi community and clinical experts as we continue to advance development of this program." Prior to Acadia's acquisition, Levo conducted a Phase 3 multi-center, randomized, double-blind, 8-week placebo-controlled study evaluating two doses of ACP-101, 3.2 mg and 9.6 mg, versus placebo three times daily with an even randomization. Top-line results showed that ACP-101 was safe and well-tolerated and demonstrated nominally statistically significant efficacy at the 3.2 mg dose.

16:07 EDT LifeVantage extends previously authorized repurchase pact to December 31, 2026 - LifeVantage announced that the Company's Board of Directors has approved an extension to the previously authorized stock repurchase program extending it until December 31, 2026. Additionally, the Company announced that it has authorized a pre-arranged stock trading plan for the purpose of repurchasing a limited number of shares of the Company's common stock in accordance with the guidelines specified under Rule 10b5-1 of the Securities Exchange Act of 1934."The extension of our stock repurchase program reflects a high degree of confidence in the trajectory of our business as we continue executing against the core priorities that underpin our LV360 strategic transformation," said Steve Fife, President and Chief Executive Officer of LifeVantage. "We have a strong balance sheet and remain committed to enhancing shareholder value through a balanced approach to capital allocation encompassing investments in growth initiatives, quarterly dividend payments and share repurchases."

16:07 EDT PepGen provides update on planned initiation of PGN-EDODM1 study - PepGen announced that while it awaits receipt of an official clinical hold letter from the FDA, the company is withdrawing its prior guidance with respect to the timeline for initiating a Phase 1 study of PGN-EDODM1 in patients with myotonic dystrophy type 1 in the first half of 2023 in any geography.

16:04 EDT Confluent up 1% at close as company hosts investor day meeting - Shares of Confluent gained 36c, or 1%, to close at $37.14 as the company hosted its investor day meeting this afternoon.

15:19 EDT User reports indicate problems at Amazon Web Services, Downdetector says - Reference Link

14:54 EDT Politan says ISS recommends Masimo shareholders vote for firm's nominees - Politan Capital Management, a 9% shareholder of Masimo Corporation, announced that independent proxy advisory firm Institutional Shareholder Services, or "ISS," has recommended shareholders vote for the election of Politan's nominees, Michelle Brennan and Quentin Koffey, to the company's board at the Annual Meeting of Stockholders scheduled for June 26.

14:34 EDT AMD shares details on next-generation Instinct accelerator for generative AI - At the "Data Center and AI Technology Premiere," AMD (AMD) announced "the products, strategy and ecosystem partners that will shape the future of computing, highlighting the next phase of data center innovation." AMD was joined on stage with executives from Amazon Web Services (AMZN), Citadel, Hugging Face, Meta (META), Microsoft Azure (MSFT) and PyTorch to "showcase the technological partnerships with industry leaders to bring the next generation of high performance CPU and AI accelerator solutions to market," the company announced in a press release related to the event. AMD unveiled a series of updates to its 4th Gen EPYC family, which it says are "designed to offer customers the workload specialization needed to address businesses' unique needs." AMD also unveiled a series of announcements showcasing its AI Platform strategy, which it says will give customers "a cloud, to edge, to endpoint portfolio of hardware products, with deep industry software collaboration, to develop scalable and pervasive AI solutions." AMD revealed new details of the AMD Instinct MI300 Series accelerator family, including the introduction of the AMD Instinct MI300X accelerator, which it calls "the world's most advanced accelerator for generative AI." AMD Chair and CEO Dr. Lisa Su stated: "Today, we took another significant step forward in our data center strategy as we expanded our 4th Gen EPYC processor family with new leadership solutions for cloud and technical computing workloads and announced new public instances and internal deployments with the largest cloud providers. AI is the defining technology shaping the next generation of computing and the largest strategic growth opportunity for AMD. We are laser focused on accelerating the deployment of AMD AI platforms at scale in the data center, led by the launch of our Instinct MI300 accelerators planned for later this year and the growing ecosystem of enterprise-ready AI software optimized for our hardware."

14:05 EDT Governor of Indiana announces plans for $3B-plus EV battery cell plant - Governor Eric J. Holcomb, board chairman for the Indiana Economic Development Corporation, announced plans to bring a more than $3B EV battery cell plant to St. Joseph County, creating 1,700 manufacturing jobs. The new battery cell plant, a joint venture between General Motors (GM) and Samsung SDI (SSNLF), is scheduled to begin operations in 2026. GM and Samsung SDI, which announced their joint venture in April, will build the plant just east of New Carlisle at Larrison Boulevard and Indiana 2 to supply GM's growing EV production needs. GM plans to install more than 1M units of annual EV capacity in North America in 2025 and accelerate from there. The new facility will house production lines to build nickel-rich prismatic and cylindrical cells and is expected to help significantly increase the accessibility and affordability of EVs. Once complete, the plant will have more than 30 GWh of capacity. Construction is planned to begin within the next year and support more than 1,000 jobs during the build.

13:57 EDT VR sales in 2023 'significantly lower' than 2022, says Circana - Circana analyst Ben Arnold said that VR sales in 2023 have been significantly lower than last year, with unit sales declining by 70%. Higher prices last summer contributed to the decline in unit-sales volume. Increased supply of current-generation game consoles has had an effect, as well, challenging VR for a portion consumers' technology spending. The biggest challenge confronting the market for VR and other mixed reality devices, however, is the lack of new, innovative products. The relatively few new headsets released over the past 18 months have focused more on niche audiences, like VR users in enterprise settings or PS5 (SONY) owners in the case of Playstation VR 2. The MR market is in search of a device that will be universally adopted. The launch of new products from Apple (AAPL) and Meta (META) importantly will broaden the selection of devices consumers have to choose from. With new hardware designs and updated specifications, there are more premium, mid-tier, and entry-level products available to suit a wider array of preferences and budgets, Arnold noted. New findings from the Circana Connected Intelligence Wearables Ownership Report confirm that men aged 25 to 34 are twice as likely to own a VR headset than the average consumer to own a VR headset; this group is also the most likely to report purchase intent for VR products (54%). The addition of new extended reality products and applications could potentially entice a different user than the young early adopters who are typically drawn to new technology products. "Though VR headsets and smart glasses will not appeal to every consumer, our current fascination with the Metaverse and other immersive digital environments requires participation from users of many stripes," the analyst added. "With an expanding market of devices, consumers have more options to experience this technology and its appeal should grow. The market for extended reality devices will only get more crowded from here - brands that deliver the best experiences and capture the most engaged audiences will win." Reference Link

13:52 EDT Embracer Group names Matthew Karch interim COO, Phil rogers interim CSO - Embracer Group as appointed Matthew Karch as interim Chief Operating Officer. In addition, Phil Rogers, has been appointed interim Chief Strategy Officer, a newly created position. Both will join Embracer Group's Executive Management Team. Matthew Karch will resign as board member of Embracer Group at the annual general meeting 2023 and resign as CEO of Saber Interactive immediately. Phil Rogers will remain as CEO of Crystal Dynamics - Eidos. Matthew Karch, new interim Chief Operating Officer, and Phil Rogers, new interim Chief Strategy Officer, will co-lead the planning and implementation of the comprehensive restructuring program, presented by Embracer Group today, in close collaboration with management across operative groups. Matthew Karch is currently a board member of Embracer Group but will resign from this position at the annual general meeting 2023. He also resigns as CEO of the operative group Saber Interactive effective immediately. In this role he is replaced by Saber Interactive's COO Andrey Iones. Phil Rogers is currently the CEO of the operative group Crystal Dynamics - Eidos and will remain in that position along with the new interim role.

13:14 EDT BIO-key regains compliance with Nasdaq listing rules - BIO-key International announced that following the filing of its Form 10-Q for the quarter ended March 31, 2023, The Nasdaq Stock Market, LLC has informed the company that it has regained compliance with Nasdaq Listing Rule 5250(c)(1) which requires the timely filing of all required periodic financial reports with the Securities and Exchange Commission. The company's Form 10-Q filing was delayed because the compilation and review of certain financial information could not be completed within the prescribed time period without unreasonable effort and expense, BIO-key said.

12:32 EDT DoubleVerify announces partnership agreement with TVision - DoubleVerify announced a partnership with TVision, a provider of second-by-second analysis of how viewers are watching TV, to enhance performance measurement across Connected TV and provide a comprehensive and scalable attention offering in the market. DoubleVerify and TVision are joining forces to combine DV's scalable ad exposure data, including viewable time and screen share, with TVision's viewer presence and eyes-on-screen ad attention signals, the company said in a statement. "Our alliance with TVision is a significant stride towards comprehensive and reliable attention measurement in CTV," said Daniel Slotwiner, SVP of Attention at DoubleVerify.

12:12 EDT Entain announces proposed placing of new ordinary shares - Entain plc, together with its subsidiaries, announces its intention to conduct an equity raise of approximately GBP 600M through a non-pre-emptive placing of new ordinary shares in the capital of the company to institutional investors. Concurrently with the placing, the company will today make a separate offer of new ordinary shares of EUR 0.01 each in the capital of the company via PrimaryBid, to provide retail investors with an opportunity to acquire retail offer shares. A separate announcement will be made shortly regarding the retail offer and its terms, the company said. Entain has separately announced today that Entain CEE is launching a tender offer to acquire 100% of STS Holding S.A., a sports-betting operator in Poland listed on the Warsaw Stock Exchange. Entain CEE is Entain's venture in Central and Eastern Europe together with its partner EMMA Capital - Entain and EMMA will fund the offer in proportion to their current shareholding in Entain CEE.

12:07 EDT ProKidney: Previous financial guidance remains unchanged - ProKidney's previous financial guidance remains unchanged, anticipating that cash as of March 31, 2023, will fund operations through the reporting of interim results from proact 1, expected in late 2024.

12:00 EDT Scor ADR falls -6.0% - Scor ADR is down -6.0%, or -$1.75 to $27.18.

12:00 EDT Methode Electronics falls -19.3% - Methode Electronics is down -19.3%, or -$8.70 to $36.37.

12:00 EDT Allego rises 22.4% - Allego is up 22.4%, or 63c to $3.44.

11:48 EDT Priveterra Acquisition Corp trading resumes

11:40 EDT Egan-Jones recommends WisdomTree investors vote for removal of Salerno - ETFS Capital Limited, the largest combined owner of common stock, 1c par value, and Series A Non-Voting Convertible Preferred Stock of WisdomTree, with ownership of approximately 10.2% of the outstanding Common Stock, which together with its Series A Preferred Stock would represent approximately 18.3% of the company's outstanding Common Stock on an as-converted basis, today announced that a third independent proxy advisory firm, Egan-Jones Proxy Services, recommended that WisdomTree stockholders vote for change in the boardroom. In its report, Egan-Jones recommended WisdomTree stockholders vote FOR all three ETFS Capital nominees on the GOLD proxy card, for election to WisdomTree's board of directors at the upcoming annual meeting of stockholders. The Egan-Jones recommendation follows recommendations for boardroom change at WisdomTree from Institutional Shareholder Services Inc. and Glass, Lewis & Co.

11:23 EDT PNC Financial: Quarter playing out as expected, NII in line - Says deposit balances match trends in industry data. Says bank plans to continue bolt-on acquisitions. Comments taken from the Morgan Stanley US Financials Conference.

11:02 EDT Genius Brands announces name change to Kartoon Studios - Genius Brands International announced that the Company will be changing its name to Kartoon Studios. In connection with the name change, the Company plans to transfer its listing from the Nasdaq Capital Market to the NYSE American exchange. Kartoon Studios is expected to commence trading on the NYSE American exchange when markets open on Monday, June 26, 2023. Effective that date, the Company's common stock will begin trading under a new trading symbol, "TOON," and a new CUSIP number, 37229T 509. The Company will continue to trade on Nasdaq under its current trading symbol, "GNUS" until the close of market on Friday, June 23, 2023.

10:37 EDT U.S. Bancorp: New rules to dictate capital deployment

10:25 EDT U.S. Bancorp reiterates FY23 NIM guidance of 3%-3.05%

10:21 EDT U.S. Bancorp: Loans flat, deposits relatively stable

10:11 EDT RiceBran appoints Eric Tompkins as executive chairman - RiceBran Technologies announced that Eric Tompkins has joined the Company's Board of Directors and been named Executive Chairman. In addition, Peter Bradley, Executive Chairman, Will Black and Jean Heggie have resigned from the Board. The changes to the Board are effective immediately. Tompkins joined RiceBran in 2019.

10:00 EDT Scor ADR falls -6.8% - Scor ADR is down -6.8%, or -$1.96 to $26.97.

10:00 EDT Manchester United rises 11.9% - Manchester United is up 11.9%, or $2.40 to $22.53.

10:00 EDT Allego rises 20.3% - Allego is up 20.3%, or 57c to $3.38.

09:47 EDT ProShares UltraShort Bloomberg Natural Gas falls -6.6% - ProShares UltraShort Bloomberg Natural Gas is down -6.6%, or -$5.35 to $76.28.

09:47 EDT Emeren rises 8.1% - Emeren is up 8.1%, or 29c to $3.87.

09:47 EDT Metals Acquisition rises 11.6% - Metals Acquisition is up 11.6%, or $1.16 to $11.20.

09:44 EDT Charlotte's Web recommends shareholders vote for company nominees - The company said, "Charlotte's Web Holdings comments on certain demands made to the Company's Board of Directors by Joel and Jesse Stanley in connection with the Company's upcoming June 15, 2023 annual general shareholder meeting. Late afternoon on Friday, June 9, 2023, Joel and Jesse delivered a letter to the Board demanding that the Board take immediate steps to facilitate the replacement of a majority of Board members, including all but one of the independent Board members with four individuals selected by Joel and Jesse. Two of the four individuals proffered were Joel and Jesse themselves and one of the individuals is their long-standing business associate. The Letter provided that the Board acquiesce to their demands within 48 hours of receipt of the Letter. Both the Letter, and a subsequent press release issued by Joel and Jesse on June 12, 2023, advise that they have communicated with certain Company shareholders in an effort to reconstitute the Board. The Letter demanded that the Board waive the application of the Company's advance notice by-laws, which are designed to ensure that the Corporate Governance and Nominating Committee and the Board have sufficient time to vet potential Board nominees, including with respect to suitability and independence. Joel and Jesse's demands generally, and the timing specifically, are designed to circumvent the procedures and processes in place to protect shareholders and allow them to make an informed decision with respect to the election of directors. There are significant ongoing business relationships between Charlotte's Web and entities in which Joel and/or Jesse hold direct or indirect interests, certain of which are or will be subject to Board review and approval in the near future. The Board does not intend to abrogate its fiduciary responsibilities to shareholders by facilitating the removal of three independent Targeted Directors in favor of non-independents. This would effectively hand control of the Company to individuals of which at least two have significant conflicts of interest and who have elected to avoid appropriate vetting procedures. Such procedures are designed to, among other things, protect shareholders from conflicts of interest. The Board has a duty to act in the best interests of all its shareholders and to protect Company assets. The Board and the Company intend to comply with all legal requirements and appropriate protocols, as well as TSX and shareholder-approved Company policies, in connection with the election and appointment of any Board members. The Company notes that both ISS and Glass Lewis have recommended shareholders vote "FOR" the appointment of the nominees described in the Company's Meeting information circular."

09:41 EDT Panbela Therapeutics Inc trading halted, volatility trading pause

09:37 EDT Metals Acquisition Corp trading resumes

09:35 EDT IPX Stock trading resumes

09:32 EDT Metals Acquisition Corp trading halted, volatility trading pause

09:30 EDT Rennova Health expands services at Big South Fork Medical Center - Rennova Health announced its critical access hospital in Oneida, Tennessee has received notice from Medicare that it can now be reimbursed using a "swing bed" payment model. According to the 2020 CMS interpretive guidelines for swing beds in Critical Access Hospitals, "a 'swing-bed' is a change in reimbursement status." As a payment model, then, a CAH can use its beds interchangeably for either acute care or post-acute care. The reimbursement "swings" from billing for acute care services to billing for post-acute skilled nursing services, despite the fact that the patient usually stays in the same bed in the same physical location. A local swing bed program also directly impacts local rural residents. As a patient-centric post-acute care solution, rural patients who find themselves too well to stay in an urban hospital but too sick to go back to their own homes can return to their rural community hospitals for further care.

09:29 EDT BCI signs agreement in support of proposed Bunge, Viterra merger - British Columbia Investment Management Corporation has signed a definitive agreement in support of the proposed merger between Viterra and Bunge. BCI owns 10 per cent of Viterra and will exchange its ownership for a minority stake in the combined entity and cash upon the close of the transaction. Canada Pension Plan Investment Board and Glencore PLC will also become shareholders of Bunge. The transaction is expected to close in mid-2024, subject to the satisfaction of customary closing conditions, including receipt of regulatory approvals and approval by Bunge shareholders.

09:27 EDT Citizens Financial Services reports preliminary merger election results - Citizens Financial Services (CZFS) reported the preliminary results of the elections regarding the merger consideration to be received by stockholders of HV Bancorp (HVBC) in HVBC's pending merger with CZFS. CZFS and HVBC anticipate closing the transaction on June 16, subject to the satisfaction of customary closing conditions. HVBC stockholders were entitled to elect to receive either $30.50 in cash or 0.4040 shares of CZFS common stock for each share of HVBC common stock. Based on the preliminary election results, of the 2,242,421 shares of HVBC common stock outstanding as of the record date for the election process, holders of 888,303 shares, or 39.61%, elected to receive CZFS common stock; holders of 985,979 shares, or 43.97%, elected to receive cash; and holders of 368,139 shares, or 16.42%, did not make a valid election or did not express a preference.

09:27 EDT Splash Beverage launches TapouT Cognitive Energy drink - Splash Beverage Group announced the official launch of TapouT Cognitive Energy, an all-new sparkling 10-calorie beverage in three distinct flavors: Cherry Lemonade, Orange, and Peach Mango. Production for the new TapouT Energy Drink has been completed and it will be making its way to distributors and into retail stores now and this summer. The product will be available at tapoutdrinks.com before the July 4th holiday.

09:26 EDT VirnetX announces technology alliance partnership with ObjectSecurity - VirnetX announced a technology alliance partnership with ObjectSecurity, a company that solves complex, evolving defense and industrial cybersecurity and supply chain risk challenges that threaten national security and production downtime. VirnetX and ObjectSecurity have leveraged their patented technologies to deliver a solution available through the International Association of Certified ISAOs

09:23 EDT Intapp announces data from Orbis M&A database can be accessed via DealCloud - Intapp announced that data from the Orbis M&A database can now be accessed via its DealCloud platform. The Orbis M&A database is a proprietary database from Bureau van Dijk, a Moody's Analytics company, which consists of more than 2.5 million global deals and provides streamlined access to global mergers and acquisition data for investors and advisors. Through this partnership, Intapp clients subscribing to Bureau van Dijk's Orbis M&A database can now directly access that data within the Intapp DealCloud platform. This enhanced partnership combines completed and rumored deal data with resulting financials and vendor involvement to drive valuable network insights, boost business development efforts, and better inform data-driven decision-making.

09:22 EDT Precipio enters collaboration with academic healthcare institution - Precipio entered into a collaboration agreement with a NY-based academic healthcare institution to jointly develop a panel for Glioblastoma, an aggressive brain cancer based on Precipio's HemeScreen technology.Precipio will design and develop a panel that combines a select number of genes that provide prognostic and therapeutic markers for this form of cancer. The institution will contribute patient samples for the development process, its clinical know-how and expertise of its clinicians, and it intends to be the first to use the panel clinically once the panel development is completed. Precipio's R&D team estimates a development time of under 4 months for this assay, and a cost of less than $50,000, an unprecedented speed and development cost in this industry.

09:20 EDT BurgerFi announces Chris Jones as CFO - BurgerFi International is announcing a change in senior leadership as Christopher Jones will be joining as Chief Financial Officer on July 10 . Mr. Jones is replacing the current Chief Financial Officer Mike Rabinovitch, who is transitioning to Lionheart Capital as a Senior Advisor. Lionheart Capital along with its founder and the Company's Executive Chairman Ophir Sternberg, is the Company's largest shareholder. Mr. Rabinovitch will remain in his role as company Chief Financial Officer until July 10, and is then expected to remain with the Company and assist in the transition with Mr. Jones until July 31 r earlier if agreed to between the Company and Mr. Rabinovitch. "Mike has been an instrumental part of BurgerFi's story. We have benefitted from his unwavering commitment and leadership these past few years and we are grateful for the strong foundation he leaves behind," said Ophir Sternberg, Executive Chairman of BurgerFi International Inc. and Founder & CEO of Lionheart Capital. "I want to thank him for his partnership and willingness to support a seamless transition with Chris before becoming a Senior Advisor with Lionheart Capital."

09:18 EDT LiveOne to launch PodcastOne TV - LiveOne announced the upcoming launch of PodcastOne TV, a new linear free ad-supported streaming TV channel this summer. In partnership with MuxIP, the channel will expand distribution of PodcastOne's video content from its slate of award-winning podcasts, including The Adam Carolla Podcast, Nappy Boy Radio with T-Pain, and People's Choice Award-nominated Off the Vine with Kaitlyn Bristowe. MuxIP's FASTHub for OTT platform will enable global streaming distribution of the PodcastOne TV channel across major platforms like Pluto, Amazon FreeVee, Roku, Samsung TV Plus, LG Channels and Tubi.

09:16 EDT Genius Brands' Kartoon Channel! celebrates launch of 'Shaq's Garage' on Pluto TV - Genius Brands International celebrates the launch of Kartoon Channel!'s June 5th premiere of the all-new action-adventure comedy series for children, "Shaq's Garage," starring and executive produced by the legendary Shaquille O'Neal, on Pluto TV. "Shaq's Garage" pilot episode on Pluto TV attracted twice the users and captured twice the view time as any other show on Kartoon Channel! this year, and outperformed the average episode by over 10x over the past 90 days. The show registered over 25% of all viewers for the channel on launch day. Launch efforts included a variety of marketing support, both on and off Pluto TV.

09:14 EDT Union Pacific affirms prior guidance regarding volume, price, capital allocation - In a regulatory filing, Union Pacific disclosed that on June 13, Jennifer Hamann, Executive Vice President and CFO of the company and Eric Gehringer, Executive Vice-President - Operations of Union Pacific Railroad, the principal operating subsidiary of the company, addressed the 2023 Wells Fargo Industrial Conference. "Hamann stated that the company would incur a one-time pre-tax expense of around $70M dollars in the second quarter of 2023 from ratification of a crew staffing agreement with International Association of Sheet Metal, Air, Rail and Transportation Workers, or SMART-TD. This expense is expected to increase the company's second quarter operating ratio by around 120 basis points. The added labor expense in 2023, combined with lower business volumes and increased operating costs will likely result in a full year 2023 operating ratio that exceeds 2022 levels. In addition, a recent change in the Nebraska State income tax rate is expected to add nearly $75M to after-tax income in the second quarter 2023. Ms. Hamann also reaffirmed prior guidance regarding volume, price and capital allocation," the company stated in its filing.

09:12 EDT VivoPower's Tembo enters collaboration with AL TAIF - Tembo E-LV has signed a memorandum of understanding with AL TAIF Technical Services. Pursuant to the Agreement, the collaboration will undertake feasibility studies with a goal of formalising a partnership spanning distribution of Tembo EV conversion kits, research & development, training in electric mobility and high voltage, as well as local assembly operations in the UAE.

09:11 EDT Beyond Meat debuts newest iteration of Beyond Sausage at 15,000 outlets - Beyond Meat launches the newest iteration of Beyond Sausage. Beyond Meat is proud to introduce its newest innovation at more than 15,000 retail stores nationwide including Kroger, Albertsons, Ahold, and Publix.

09:09 EDT AREX Capital urges Enhabit board to launch review of strategic alternatives - AREX Capital Management, the owners of approximately 4.5% of the shares of Enhabit, issued an open letter to the Company's Board of Directors, which read in part, "We have appreciated the conversations with you over the past few weeks. We initially reached out to Enhabit's Board of Directors to express our frustration with the Company's poor operational and share price performance, and to offer suggestions that would benefit the Company and its shareholders. We are pleased that the Board has begun interviewing the two director candidates we suggested, and we are confident you will find them highly qualified and additive to the Board's skills matrix. However, the broader issue of Enhabit's future as a standalone public company must be addressed....Despite the Company's secular growth opportunity and attractive business model, Enhabit's shares are down ~47% since its spin-off from Encompass on July 1, 2022-and during that same period, the S&P 500 and Russell 2000 indices have appreciated by ~16% and ~11%, respectively.1 In fact, Enhabit's shares have underperformed all of the peer group members outlined in its recent proxy statement. Although it is true that the home health and hospice industries have recently faced unique regulatory and operational challenges, Amedisys, arguably the public company most similar to Enhabit, saw its shares decline by far less than Enhabit's over this period-even prior to Amedisys' recent M&A-driven increase. In our opinion, Enhabit's poor share price performance on both an absolute and relative basis is primarily self-inflicted, as a surprisingly large number of missteps have badly eroded confidence in management and contributed to a deeply discounted valuation. In our experience, when such mistakes occur early in a newly public company's journey, it can be incredibly difficult for that company to emerge from the "penalty box" with investors-even with vastly improved execution over an exceedingly long period. At the same time, the secular trend towards value-based care has substantially increased the strategic value of home health businesses, as evidenced by Humana's acquisition of Kindred at Home, UnitedHealth's acquisition of LHC Group, and most recently by Option Care Health's announced acquisition of Amedisys, which was followed by an even higher bid from UnitedHealth. In fact, once the Amedisys deal closes, Enhabit will be the last remaining publicly traded company focused primarily on home health, and our diligence suggests that there are many market participants who would logically have interest in acquiring Enhabit... We are not privy to the details of the strategic review that Encompass conducted that ultimately resulted in Enhabit's July 2022 spin-off. However, it is widely believed that the Encompass board rejected bids dramatically above the Company's current valuation, and above even an optimistic view of where Enhabit's shares could trade in the foreseeable future as a standalone company...We believe Enhabit's Board should immediately commit to shareholders that it will commence a review of strategic alternatives before the end of 2023, with an eye towards a potential transaction closing shortly after the two-year anniversary of the spin-off to avoid any tax complications. The road to fully restoring an independent Enhabit's credibility and valuation is long, arduous, and fraught with operational, public market, and other risks. Given Enhabit's objectively challenged execution and share price performance, the Board should fully explore the potential delivery of substantial and fair value to shareholders through a sale of the Company. We are highly confident that a full and fair strategic alternatives review will make it very clear to the Board that, as compared to the risks and potential rewards inherent in the status quo, a sale is the obvious way to maximize value for all shareholders. We understand that in the very short term the Company must consider spin-off tax rules and its Tax Matters Agreement with Encompass, but we are certain that a review of alternatives can be commenced within the time frame we described. In the meantime, our director candidates are prepared to join the Board where they could immediately provide valuable operational and strategic insights and could later guide the Company through its strategic alternatives review. If the Board is unwilling to make this important and appropriate commitment to shareholders, we will consider all options at our disposal to ensure that shareholder value is maximized and that the Board is held accountable."

09:07 EDT F5 Networks, MazeBolt Technologies announce technology partnership - MazeBolt Technologies announced a new technology alliance partnership with F5 Networks. This technology alliance is focused on allowing mutual customers of MazeBolt and F5 to experience streamlined remediation of vulnerabilities identified in their DDoS protections. A preferred remediation vendor has been identified by MazeBolt to be competent and cooperative in facilitating this process. MazeBolt RADAR, together with F5, allow companies to obtain critically important information on DDoS vulnerabilities and remediate them quickly.

09:05 EDT Senmiao Technology reports ride-hailing platform metrics for May - Senmiao Technology announced the operating metrics for its proprietary online ride-hailing platform for the month of May 2023. In May 2023, Senmiao and its affiliates recorded approximately 0.8M total completed orders, compared to approximately 0.9M total orders completed in April 2023. The decrease was due to increased competition in the Chengdu market as a result of new ride-hailing platforms launching and offering promotions during the month.

09:04 EDT Oracle to develop generative AI services for organizations worldwide - Oracle announced its plans to develop powerful, generative AI services for organizations worldwide. Oracle will provide native generative AI services to help organizations automate end-to-end business processes, improve decision-making, and enhance customer experiences, in collaboration with Cohere, a leading AI platform for enterprise. Built on Oracle Cloud Infrastructure and leveraging Oracle's unique Supercluster capabilities, Oracle generative AI services will span applications to infrastructure and aim to provide the highest levels of security, performance, and value in the industry. Through the partnership, Cohere will train, build, and deploy its generative AI models on OCI. OCI is uniquely positioned to run AI workloads as it delivers the highest performance and lowest cost GPU cluster technology, with scale of over 16K H100 GPUs per cluster, and very low latency and the highest bandwidth RDMA network in the cloud. This will enable the acceleration of large language models training while simultaneously reducing the cost.

09:03 EDT Frontier Group partners with APiJET to test route optimization technology - Frontier Airlines and APiJET, a provider of real-time flight optimization for fuel and carbon savings, signed an agreement to test APiJET's Digital Winglets for operations centers. Digital Winglets utilizes TASAR - Traffic Aware Strategic Aircrew Requests -, a technology initially developed by NASA and refined and productized by APiJET, that analyses hundreds of variables and potential flight paths in real-time to provide route optimizations that result in fuel and carbon savings.

09:02 EDT Hitachi Vantara, Cisco sign new strategic partner agreements - Hitachi Vantara, the modern infrastructure, data management and digital solutions subsidiary of Hitachi (HTHIY), announced two new global partnership agreements with Cisco (CSCO). The agreements bring Hitachi Vantara into Cisco's Service Provider and Solution Technology Integrator partner programs, respectively, enabling Hitachi Vantara to seamlessly integrate Cisco technologies with its storage products and position the company as a leading data center infrastructure and hybrid cloud managed services provider.

08:54 EDT Zions Bancorp sees Q2 net interest margin 'trending toward 2.85%' - In Slide 26 of the company's investor presentation released last night in an 8-K filing, the company states that the projection is an update as of June 12th. The company's Q1 net interest margin was 3.33%. Shares of Zions Bancorp are down 3.1% in pre-market trading at $29.30. Reference Link

08:51 EDT NaaS to acquire over 89% stake in Sinopower HK for $6.1M - NaaS Technology announced that Dada Auto has entered into a definitive agreement to acquire 89.99% of the issued and outstanding shares of Sinopower Holdings International from an existing shareholder of Sinopower, for an aggregate purchase price of approximately $6.1 million in cash. The share purchase is subject to customary closing conditions and is expected to close in June 2023. Sinopower HK specializes in Estates and commercial/industrial rooftop solar PV project development. Apart from the 25MW distributed solar energy project, the company has hitherto developed and built over 600 solar energy projects in Hong Kong. In Hong Kong's Estates and commercial/industrial rooftop distributed solar energy market, Sinopower HK has total supremacy, as well as rooftop solar energy projects of substantial numbers of industrial and commercial blocks in Hong Kong, e.g., design and construction of solar energy power station of the HKEX building and the terminal building for the third runway of Hong Kong International Airport. The deal will engage the parties in all-rounded and deep integration in technology, product, capital and market. Making a foray into HK's distributed solar energy sector, NaaS takes a significant step in its go-global business and continues to deliver new energy products and service solutions worldwide; Sinopower HK, on the other hand, will leverage NaaS' competence and marketing experience in charging services and platform advantage as a listed company to bring its existing rooftop solar PV business to a new level while deploying community resources built up in its rooftop solar energy business development in HK's charging pile operation market and gaining greater room for development through a transformation towards an integrated new energy service provider.

08:48 EDT GameStop jumps 6.4% in premarket trading after Cohen slightly boosts stake

08:47 EDT Journey Medical says Phase 1 trial of DFD-29 achieved all primary objectives - Journey Medical (DERM) announced topline data from the Phase 1 clinical trial assessing the impact of DFD-29 on the microbial flora of healthy adults. The clinical trial also assessed the safety and tolerability of the treatment. DFD-29 is being developed for the treatment of papulopustular rosacea in collaboration with Dr. Reddy's Laboratories (RDY). DFD-29-CD-006 is a multi-center, randomized, double-blind, placebo-controlled, parallel group study that enrolled 60 healthy, adult subjects in a 2:1 randomization between DFD-29 and placebo. Treatment was administered once daily orally over 16 weeks. Microbiological samples were collected from the skin, stool and vagina at multiple timepoints through the study. The study achieved all primary objectives and no significant safety issues were noted during the study. Treatment with DFD-29 for 16 weeks did not produce significant negative impact on the normal microbial flora and did not induce significant bacterial resistance. Additionally, treatment with DFD-29 did not cause significant proliferation of opportunistic organisms. The results indicate that DFD-29 can be safely used for up to 16 weeks with no significant risk of microbiota suppression or development of resistance. The DFD-29 Phase 3 clinical program consists of two multicenter, randomized, double-blind, parallel-group, active-comparator and placebo-controlled clinical trials, MVOR-1 and MVOR-2, that are expected to support a New Drug Application submission in the United States and a Marketing Authorization Application in Europe. The combined enrollment target of 640 total adult patients with moderate to severe PPR was achieved in the trials; one trial enrolled patients in the United States, and the other enrolled patients in both the United States and Europe. The MVOR-1 and MVOR-2 clinical trials are randomized in a 3:3:2 ratio to DFD-29, Oracea or Placebo once daily for 16 weeks. The primary objective is to evaluate the safety, efficacy and tolerability of DFD-29 compared to placebo for the treatment of PPR. The secondary objective is to evaluate the safety, efficacy and tolerability of DFD-29 compared to Oracea. To date, no major safety issues have been reported, and no drug-related serious adverse events have been observed.

08:44 EDT Archer Aviation appoints Billy Nolen Chief Safety Officer - Archer Aviation has appointed Billy Nolen, former acting FAA Administrator, as its Chief Safety Officer. Nolen's expertise in aviation safety and flight operations, along with his deep passion and excitement for advanced air mobility, will further strengthen Archer's ability to successfully commercialize urban air mobility at scale. While at the FAA, Nolen led the agency's efforts to enable the safe entry of eVTOL aircraft into the national airspace. Nolen has been a strong advocate for the eVTOL aircraft industry and its role in changing the way the world moves. In his new position, Nolen will play a leadership role to help Archer more effectively collaborate with industry stakeholders and help ensure its safe entry into service as it prepares for planned commercialization in 2025.

08:41 EDT VCI Global engaged as Sagtec Group's IPO, business expansion consultant - VCI Global nnounced that its wholly owned subsidiary, V Capital Consulting has been appointed as Sagtec Group's initial public offering consultant. This is in conjunction with SAGTEC's proposed listing on the NASDAQ stock market. This IPO advisory mandate entails a $2M advisory fee and a success fee of 5% of the market capitalisation of SAGTEC when listed. As the IPO consultant, VCCL's scope of work, amongst others, includes:- review and assist with the reorganization of SAGTEC's capital structure; establish capital market strategies to maximize SAGTEC's value ahead of the listing exercise; where applicable, review and assist in responding to queries from U.S. Securities and Exchange Commission and NASDAQ; and prepare and assist in obtaining all requisite regulatory approvals. VCCL's consultancy expertise was further sought as SAGTEC also appointed VCCL as its business expansion consultant in connection with SAGTEC's plans to expand its business into the Southeast Asia region. On this note, VCCL will conduct feasibility studies and competitive analysis to understand the competitive landscape within the said region. As part of its job scope, VCCL will also be developing customised market strategies that complement SAGTEC's business goals on the back of the unique dynamics of the Southeast Asia region.

08:39 EDT Longeveron appoints Wa'el Hashad, Khoso Baluch, Jeffrey Pfeffer to board - Longeveron announced the election of three new directors to serve on the Longeveron Board of Directors. Wa'el Hashad, Khoso Baluch, and Jeffrey Pfeffer were elected at the Company's Annual Meeting of Stockholders, held Friday June 9, 2023, and will serve until the 2026 Annual Meeting of Stockholders, or until their successors are duly elected. Concurrent with the election of the new Directors, the terms of Donald Soffer, Erin Borger, and Todd Girolamo to serve as directors expired. Wa'el Hashad has served as CEO of Longeveron since February, 2023. Khoso Baluch has served as an independent director of Poxel S.A., a French publicly traded biotech company, chairs its compensation committee and as of March 2023 became Chairman. Jeffrey Pfeffer is the Thomas D. Dee II Professor of Organizational Behavior at the Graduate School of Business, Stanford University, where he has taught since 1979.

08:37 EDT Datasea announces joint publication on 5G messaging services - Datasea announced the joint publication of the, "Research Report on 5G Messaging Services in the Express Delivery Industry" in collaboration with the China Academy of Information and Communications Technology, SF Taisen Holdings and others. The report was unveiled at the recently held, "5G Messaging Development Practice Forum" co-organized by CAICT, the China Communications Enterprises Association, and the 5G Messaging Working Group. The forum took place at the National Convention Center in Beijing, where industry professionals gathered to discuss the future of 5G messaging development. The jointly-published report provides an robust dissection of the current landscape of messaging services in the express delivery sector and the capabilities of 5G messaging. It highlights key application areas including business marketing, customer service, express services, service assessment, and potential areas for enhancement. Furthermore, the report underscores the inherent value of 5G messaging in daily operations and maps out a trajectory for a future where the express delivery industry is seamlessly integrated with 5G messaging.

08:36 EDT Ruth's Hospitality announces opens for business in Mt. Pleasant, Michigan - "Ruth's Chris Steak House, famous for its unmatched dining experience and steaks served on 500-degree sizzling plates, today announced its newest location is open for business in Mt. Pleasant, Michigan inside the Soaring Eagle Casino and Resort. Ruth's Chris Steak House announced its newest location in Mt. Pleasant, which is now open for business. It is located at 6800 Soaring Eagle Blvd The Mt. Pleasant Ruth's Chris restaurant, located at 6800 Soaring Eagle Blvd., brings an unmatched dining experience to the Central Michigan area with its 8,965 square-foot location. The new space features three main dining rooms, a luxurious bar and bar-lounge, patio with ample seating, as well as a private dining room that can accommodate personal and family celebrations, business meetings and more. The space is elegantly appointed and thoughtfully designed to provide a comfortably elegant, warm, and welcoming dining experience for every guest," said the company in a statement.

08:34 EDT Odyssey Marine CFO Christopher Jones to depart - Odyssey Marine announced that Christopher Jones, Odyssey's CFO will leave the company on July 7 to pursue another opportunity. Jones will continue to support Odyssey in an advisory role after his departure. Odyssey intends to appoint an experienced interim CFO, while Odyssey searches for a permanent CFO with a skill set that aligns with Odyssey's future growth plans. During this period, the company expects to reduce its administrative expenses but will continue to have appropriate management and controls in place.

08:33 EDT Sabre and Air Canada enter strategic distribution & retailing partnership - Sabre (SABR) has completed a new multi-year distribution agreement that provides Sabre-connected agencies with long-term access to Air Canada's (ACDVF) full content via NDC channels. Under the agreement, Sabre will be able to provide agencies with content and offers from Air Canada, including the airline's dynamically priced fares and new ancillary services. The two companies expect to activate Air Canada's NDC content in Sabre within the coming months. Once Air Canada's NDC connection to Sabre is live, the Distribution Cost Recovery previously announced by Air Canada will be waived for Sabre-connected travel agencies using this path.

08:29 EDT Panbela Therapeutics enters sponsored research agreement with MD Anderson - Panbela Therapeutics entered into a sponsored research agreement with The University of Texas MD Anderson Cancer Center for the evaluation of polyamine metabolic inhibitor therapies in combination with CAR-T cell therapies in preclinical models. The initial goal of these studies will be to ascertain if eflornithine and/or ivospemin treatment will augment CAR-T mediated cytotoxicity against CD19+ large B-cell lymphoma cell lines. Recently, a metabolite panel primarily consisting of polyamines was identified as predictive of poor response to anti-CD19 CAR T-cell therapy in relapsed refractory LBCL. Additionally, the polyamine uptake transport system is upregulated in LBCL and multiple myeloma. Together, this suggests the potential for a polyamine targeted therapy in combination with CAR-T therapies.

08:27 EDT Silo Pharma enters research, development agreement for ketamine implant - Silo Pharma announced its entry into a research and development agreement to study and develop a dosage and time-release ketamine implant for the treatment of fibromyalgia. The research project includes analytical testing services and small batch pre-clinical proof of concept extrusion trials to determine drug release and stability.

08:25 EDT BIO-key updates Admin Panel of PortalGuard IDaaS platform - BIO-key International announced a significant update to the Admin Panel of PortalGuard IDaaS. This update provides enhanced support for MSPs and MSSPs to enhance their authentication and operational efficiency, enabling the best service possible for their customers.

08:22 EDT Bionano Genomics announces presentation of OGM utility at ISSCR meeting - Bionano Genomics announced its participation in the International Society for Stem Cell Research Annual Meeting 2023 with a broad range of content covering the utility of optical genome mapping for research, development, and manufacturing applications in stem cell therapy. ISSCR's annual meeting brings together industry, medical, and academic professionals to discuss advances in stem cell research and regenerative medicine. The ISSCR conference will be held June 14-17, 2023, online and in-person in Boston, Massachusetts. As part of a sponsored session titled "Optical Genome Mapping - Redefining Cell Line Genomic Integrity and Off-target Characterization," three experts will share their experiences using OGM in their research, development and manufacturing processes. Presentations will cover OGM's utility for monitoring genomic integrity and off-target effects in cell lines and its potential to improve the quality, safety, and overall risk profile of next-generation therapy development and manufacturing. Dr. Alex Hastie, Dr. Suk See De Ravin from National Institute of Health and Travis Hardcastle from Synthego will present in Room 255 on Friday, June 16, 2023, at 11:30 am ET.

08:20 EDT Avadel Pharmaceuticals announces publication of survey data on oxybate - Avadel Pharmaceuticals announced the publication of survey data describing clinician preferences among oxybate treatments for patients living with narcolepsy. The paper, titled "Clinician Preferences for Oxybate Treatment for Narcolepsy: Survey and Discrete Choice Experiment," was published in Advances in Therapy. Discrete choice experiments are studies designed to characterize and quantify drivers of preferences for attributes. Clinicians selected from hypothetical, randomly generated medicine profiles to determine which medication they preferred overall, which would improve patient quality of life, and which would reduce patient anxiety and stress. Prior to the DCE, a survey to understand perspectives of first generation, twice-nightly oxybates, and other treatments for narcolepsy, was undertaken. Clinicians reported moderate to high satisfaction with immediate-release oxybate treatments; however, clinicians indicated that twice-nightly dosing was a significant stressor for patients. In the DCE, the frequency of oxybate treatment dosing was the most important driver for overall product choice, improved patient quality of life, and reduced patient anxiety and stress; once-nightly dosing was preferred over twice-nightly. The frequency of oxybate treatment dosing, driven by once-nightly dosing, was more than twice as important for overall product choice than the next two attributes, which were adverse reactions and sodium content, respectively. Similarly, frequency of oxybate treatment dosing, driven by once-nightly dosing, was more than double in relative importance, for patient quality of life and for reducing patient anxiety/stress, than other attributes. This DCE validates a previously published DCE in patients, in which dosing frequency was also shown to be the most important driver of patients' preferred oxybate treatment. These data underscore the long unmet need for an oxybate treatment that does not require middle-of-the-night dosing.

08:19 EDT Paysign completes issuer certification and connection with Mastercard - Paysign (PAYS) announced the completion of an issuer certification and connection with Mastercard (MA). This collaboration marks a significant milestone for Paysign and reinforces its commitment to delivering enhanced payment experiences for its clients and cardholders. "We are thrilled to have completed our certification and established a connection with Mastercard," said Matt Lanford, Paysign's President and COO. "This collaboration not only strengthens our position in the market but also enables us to deliver enhanced payment solutions to our clients. The expanded global network and advanced security measures offered by Mastercard will undoubtedly benefit our customers, empowering them to grow their businesses and provide exceptional payment experiences to their customers."

08:18 EDT Jin Medical releases ultralight electric wheelchairs, electric mobility vehicles - Jin Medical released a new ultralight electric wheelchair model and a new electric mobility vehicle model for the elderly. The two new models have been developed in collaboration with Nanjing Tech University. JinMed is responsible for the development and manufacturing of the new models' electrical components, while NJTech oversees the new models' style and industrial design. The new models are expected to be ready for sale this year, via multiple sales channels, including online platforms, and authorized dealerships, both in China and overseas markets. The newly released ultralight and portable wheelchair model is equipped with dual brushless motors and an electromagnetic safety brake system designed to offer reliable performance on slopes with optimal safety. Its large-capacity battery allows for an extended single-charge range of over 25km, while the quick-release battery box design offers both convenience and security. The new model has a compact and user-friendly interface, which enables 360-degree remote control and a USB plug for powering mobile devices. The new model is made of high-strength aluminum alloy materials but weighs only 21.5kg. It also features a one-button reclining function for the backrest and an adjustable headrest, providing users with the option to rest in a lying position. The newly released electric mobility vehicle model is a branded "E-Scooter" which incorporates multidimensional folding technology, so it can be folded into a compact size. Also featuring a powerful motor, safety brake design, the E-Scooter has a large display screen for precise route measurement that is powered by a GPS positioning system to facilitate a worry-free travel experience. The model provides an extended battery life, while the LED headlights are designed to make night-time travel safer. The E-Scooter's design comes in a range of colors and is also made of high-strength lightweight aluminum alloy and a carbon fiber structural skeleton.

08:16 EDT Jasper Therapeutics appoints Edwin Tucker as CMO - Jasper Therapeutics announced the appointment of Edwin Tucker as Jasper's CMO. Concurrently, Jasper also announced the appointment of Dr. Daniel Adelman, who had been serving as Jasper's Acting CMO, to its Scientific Advisory Board and to the position of Senior Clinical Advisor. Tucker was most recently Chief Medical Officer at Goldfinch Bio, where he led clinical development and helped build the regulatory, medical affairs and clinical operations functions.

08:15 EDT electroCore to present poster on nVNS at American Headache Society meeting - electroCore announced that "SUNCT/ SUNA with neurovascular conflict: consider nVNS," will be presented at the American Headache Society's 65th Annual Scientific Meeting on June 16-17, 2023 in Austin, Texas. The abstract and poster highlight the observed efficacy of nVNS in three patients with rare headache diseases, SUNCT/SUNA, in the class of headache disorders known as Trigeminal Autonomic Cephalalgia's. The retrospective study suggests that nVNS, as a treatment for TACs in general, and specifically for refractory SUNCT/ SUNA, should be considered before microvascular neurosurgery, particularly given the well-recognized risks and costs of such surgical procedures.

08:13 EDT Healthcare Triangle says Nasdaq Delisting determination was in error - Healthcare Triangle announced that the Nasdaq Stock Market Delisting Notice determination regarding the minimum closing bid price requirement for continued listing on The Nasdaq Capital Market was executed in error. In turn, Nasdaq has cancelled the Company's request to Nasdaq for a hearing to appeal its delisting determination, and the Company is no longer required to complete a compliance plan for continued listing. Nasdaq has determined Healthcare Triangle was in compliance with the minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) by May 30, 2023, the deadline to regain compliance. On May 26, 2023, the Company effected a one-for-ten reverse stock split, and as a result, the closing price of the Company's common stock has since remained greater than $2.60.

08:13 EDT Wells Fargo to do more proactive marketing over time, says CFO - Comments made by CFO Mike Santomassimo at the Morgan Stanley US Financials, Payments & CRE Conference.

08:12 EDT Wireless Telecom to showcase products at IMS 2023 - Wireless Telecom Group announced that its test and measurement brands - Boonton, Holzworth, and Noisecom - will showcase industry-leading instruments with the performance and capability necessary for accelerating the development of next-generation wireless systems during IMS 2023 at Booth 1619. Product demonstrations will feature specialized capabilities across amplifier characterization, high-performance RF signal generation, and phase noise analysis. As a test and measurement leader, the company will also host a technical session on RF and microwave power sensor technologies. Boonton will demonstrate fast-switching, low phase noise RF signal generation enabling accurate component characterization and testing of radar and communications systems. The measurement and analysis will be made with Boonton true average RF power sensors operating at the industry-fastest rate of 100,000 measurements per second. Holzworth will demonstrate broadband, low phase noise signal generation and real-time phase noise analysis, supporting the quick evaluation of a local oscillator's performance and symbol error contributions in 5G and Wi-Fi communications systems.

08:09 EDT Recursion Pharmaceuticals announces full enrollment of Phase 2 SYCAMORE trial - Recursion announced the full enrollment of its Phase 2 SYCAMORE clinical trial evaluating REC-994, a potentially first-in-class, orally bioavailable small molecule for the treatment of CCM. The Phase 2 trial is designed as a multi-center, randomized, double-blind, placebo-controlled study to investigate the safety, efficacy and pharmacokinetics of REC-994. The primary outcome is specific to safety and tolerability, measured by adverse events. The secondary outcomes center on efficacy, including clinician- and patient-reported outcomes, imaging of CCM lesions, the impact of acute stroke, as well as exploratory biomarkers.

08:08 EDT Black Diamond Therapeutics appoints Melanie Morrison as CDO - Black Diamond Therapeutics announced the promotion of Melanie Morrison from Senior Vice President, Development Operations to Chief Development Officer. As Chief Development Officer, Ms. Morrison leads the Company's clinical operations, program management and program leadership functions, and regulatory affairs.

08:06 EDT Vontier forms EVolve to accelerate e-mobility business - Vontier announced the formation of EVolve, a new portfolio entity to accelerate its growth as a leader of sustainable solutions for the e-mobility ecosystem. Powered by market leaders Driivz and Sparkion, EVolve is spearheading the rapid transition to electric mobility by providing an interoperable electric vehicle charging and energy management platform. The solution will enable EV charging providers and fleet operators to simplify and facilitate EV charging economically at scale. EVolve will be led by newly appointed President and CEO Andrew Bennett. Bennett was most recently CEO at mPrest. The first customer site EVolve will be bringing the joint solution to is Circle K, Norway, where an initial site has recently been installed. Circle K has almost 1600 charge points on their sites across Europe and is owned by the Alimentation Couche-Tard corporation.

08:05 EDT Manchester United jumps 16% after report says Sheikh Jassim winning bidder - The shares are up 16% to $23.38 in premarket trading after Qatar's Al-Watan newspaper said Sheikh Jassim bin Hamad al-Thani is likely to succeed in his takeover bid for Manchester United.

08:04 EDT Taco Bell, Crocs announce Mellow Slide limited edition collaboration - Taco Bell is teaming up with Crocs on the first-ever Mellow Slide limited edition collaboration. The iconic brands have reimagined Crocs' comfy Mellow Slides and added some heat so fans can be reminded to Live Mas with every step. With a simple, yet modern design, Crocs Mellow Slides boast a mood-boosting silhouette and blissful design to allow your feet to melt into the footbeds. Inspired by Taco Bell's signature colors, black and purple, the Taco Bell x Crocs Mellow Slides feature an ombre-like fade with "Live" and "Mas" imprinted separately in white within each footbed. The slides are perfect for a beach trip, park hang - or a quick trip to Taco Bell when a craving strikes. Mark your calendars for the drop to go nationwide on June 28, available exclusively on crocs.com, retailing for $60.

07:47 EDT Camping World launches1st wave of manufacturer exclusive locations - Camping World Holdings announced the launch of a new, industry-first dealership format that is dedicated exclusively to the RV industry's leading brands. Under this format, select individual dealerships will be dedicated exclusively to selling, servicing, and showcasing that brand's latest innovation and product offering, with a tailored, brand-specific customer experience and specialized staff training. The recent opening of Jayco Morgan Hill in California marks the first wave of this rollout. This format is designed to both complement and operate in parallel with the existing traditional Camping World branded footprint. The Company intends to open, acquire, or convert manufacturer exclusive locations across its network. Marcus Lemonis, Chairman and CEO of Camping World stated, "We believe our growth can be accelerated by acquiring or opening dealerships that will ultimately be focused exclusively on the leading RV brands in America." Matt Wagner, COO of Camping World continued, "We believe this strategy widens the acquisition funnel to include dealers with a smaller real estate format or those located near an established Camping World dealership where we have access to a multitude of brands that compete in the same segment."

07:42 EDT DavidsTea to fulfill consumer orders in-house starting in Q3 - The company said, "Sales continue to be impacted by unfavorable economic conditions that dampen consumer demand. We also believe that our e-commerce revenues have been impacted by order fulfillment difficulties encountered in the fourth quarter that left many consumers frustrated. As a result, on June 9, 2023 the Company sent a notice of termination, effective July 23, 2023, to its current fulfillment service provider and is in discussions with it concerning an orderly transition. Although the service provider has indicated that it may dispute the Company's right to unilaterally accelerate termination of the agreement, the Company is fully confident that it has the legal right to do so." "Due to persistent headwinds in the economic environment, sales declined 29.4% year-over-year to $14.3 million in the first quarter," said Frank Zitella, President, Chief Financial and Operating Officer, DAVIDsTEA. "Despite reduced sales, our gross margin remained relatively stable at 40.3% due to the numerous actions undertaken to mitigate the impact of a lower revenue run-rate. As we assessed the strengths and weaknesses of our ability to provide a best-in-class consumer experience, we concluded that a change was required in our order fulfillment operations. We are pleased to announce that starting in the third quarter, we will be fulfilling consumer orders in-house to better support the fast service and elevated brand experience consumers expect from a premium online retailer like DAVIDsTEA."

07:38 EDT Nextech3D.ai says Toggle3D to trade on CSE starting June 14 - Nextech3D.AI has received court approval for the Toggle3D.ai spinout, and the trading date on the Canadian Securities Exchange will commence on June 14, 2023. Toggle3D.ai will be trading under the ticker symbol TGGL on the CSE. The spinout will be effected pursuant to the Company's previously announced plan of arrangement which received final court approval on June 9, 2023. Nextech3D.ai shareholders will automatically receive an aggregate of 4,000,000 shares as a stock dividend. After the spin-out Nextech3D.ai is going to retain 13 million shares or about a 50% ownership stake in Toggle3D.ai. Toggle3D.ai has raised $2,158,118 pursuant to the issuance of 8,632,473 common shares and 8,632,473 $0.50 warrants.

07:35 EDT BridgeBio reports inducement grants under Nasdaq listing rule - BridgeBio Pharma announced that on June 11, 2023, the compensation committee of BridgeBio's board of directors granted 14 new employees restricted stock units for an aggregate of 76,800 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on May 16, 2024, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio's Amended and Restated 2019 Inducement Equity Plan. The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio's board of directors in November 2019, and amended and restated on February 10, 2023.

07:32 EDT Sensei Biotherapeutics to host KOL event on SNS-101 - Sensei Biotherapeutics announced that the Company will host a virtual KOL event, "A New Vista for Cancer Care: Exploring SNS-101's Potential as a Transformative Treatment Option for Patients with Solid Tumors," on Tuesday, June 27, 2023 at 2:00 p.m. ET. The event will feature James Gulley, M.D., Ph.D., Co-Director of the Center for Immuno-Oncology at the National Cancer Institute, who will provide an overview of the unmet medical need in solid tumors and the current immuno-oncology treatment landscape, and discuss the potential for Sensei's lead candidate, SNS-101, a conditionally active VISTA-blocking antibody, to improve treatment outcomes for patients with solid tumors. Sensei management will provide insight into the preclinical mechanism and profile of SNS-101, and present an overview of the SNS-101 clinical program, including collaborating with the NCI as a site for the Phase 1/2 SNS-101 clinical trial. Sensei recently announced that the first patient has been dosed in the trial at a starting dose of 0.3 mg/kg.

07:22 EDT AstraZeneca announces partnership with Vanguard Renewables - "In a first-of-its-kind collaboration, AstraZeneca is partnering with Vanguard Renewables to enable the delivery of renewable natural gas to all of its sites in the United States by the end of 2026. From June 2023, AstraZeneca will begin purchasing RNG produced by Vanguard Renewables for its Newark Campus in Delaware, where the Company packages 26 medicines for distribution across the U.S. and makes medicine formulations for global supply. By 2026, this collaboration will enable as much as 650,000 million British thermal units or 190,500 megawatt hours per year, of RNG to be used across AstraZeneca's U.S. sites, equivalent to the energy required to heat more than 17,800 U.S. homes for a year," said the company in a ststaement. Pam Cheng, Executive Vice President of Global Operations & IT and Chief Sustainability Officer at AstraZeneca, said: "We recognize the interconnection between the health of people and the planet, and are committed to driving deep decarbonization across our operations and value chain. Our innovative partnership with Vanguard Renewables in the U.S. is an illustration of how we are collaborating at scale to deliver sustainable science and medicines, as part of the transition to net zero health systems and a circular economy."

07:19 EDT Bread Financial reports net loss rate for May 8.4% vs. 6.2 % last year - Bread Financial Holdings provided a performance update .Reports net loss rate 8.4 % for the month ended May 31 vs. 6.2 % last year. Reports delinquency rate Delinquency rate 5.5 % vs. 4% last year.

07:17 EDT Aclaris Therapeutics completes enrollment in Phase 2b study of ATI-450 - Aclaris Therapeutics announced the completion of enrollment into ATI-450-RA-202, its Phase 2b trial of oral zunsemetinib in patients with moderate to severe rheumatoid arthritis. Aclaris expects to announce top-line efficacy, safety and other preliminary data from this trial in the fourth quarter of this year. ATI-450-RA-202 is a Phase 2b, randomized, multicenter, double-blind, placebo-controlled, dose-ranging study to investigate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of two doses of zunsemetinib plus methotrexate versus placebo plus MTX in patients with moderate to severe RA who have had an inadequate response to MTX alone. The study has enrolled 251 patients across the three treatment arms at over 20 trial sites in the U.S., Poland, Bulgaria and Czech Republic. The primary efficacy endpoint is the proportion of patients achieving an ACR20 response following 12 weeks of treatment. Secondary efficacy endpoints include ACR50 response, ACR70 response, DAS28-CRP and other pertinent RA measures.

07:13 EDT First Wave BioPharma reaches enrollment target for Phase 2 SPAN trial - First Wave BioPharma announced that it has achieved the enrollment target in its ongoing Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation of adrulipase for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis. The Phase 2 multi-center clinical trial is designed to investigate the safety, tolerability and efficacy of an enteric microgranule delivery formulation for adrulipase in a titrated dose-escalation study involving an estimated twelve patients. The primary efficacy endpoint is the coefficient of fat absorption, with secondary endpoints of stool weight, signs and symptoms of malabsorption and coefficient of nitrogen absorption. Topline results from the study are anticipated by mid-2023.

07:10 EDT SGH to sell 81% interest in SMART Modular Tech for approximately $166M cash - SMART Global Holdings announced that the Company, through its wholly owned subsidiary SMART Modular Technologies has entered into an agreement to sell an 81% interest in SMART Modular Technologies do Brasil, Industria e Comercio de Componentes or SMART Brazil, to Lexar Europe B an affiliate of Shenzhen Longsys Electronics for approximately $166M in cash consideration. The purchase price values 100% of SMART Brazil at an initial enterprise value of $205M. SMART Brazil operates as a stand-alone business focused on the Brazil market. It assembles and tests modules for electronics manufacturers that sell devices to Brazilian consumers. These manufacturers turn to SMART Brazil for reliable, standards-based modules that are assembled in Brazil. "The majority divestiture of our standards-based, commodity module business in Brazil will enable SGH to focus on our strategy of delivering high-performance, high-availability solutions to our enterprise customers," said Mark Adams, chief executive officer of SGH. "This transaction will strengthen our financial position, enabling us to increase our strategic investments into domestic research and development, and US-based production of advanced technologies." Transaction Summary Under the terms of the agreement, the purchase price values 100% of SMART Brazil at an initial enterprise value of $205M. This amount has two separate components, an upfront value of $170 million and a deferred value of $35M. At closing, SGH will receive an upfront cash purchase price of $137.7M , subject to certain customary adjustments, for 81% of SMART Brazil's outstanding equity. Eighteen months following the closing SGH will receive a deferred cash payment of $28.35M. In addition to the upfront and deferred cash payments, SGH will retain a 19% interest in SMART Brazil. During three exercise windows between 2027 and 2029, the parties have a put and call feature for the remaining stake at a put/call price that values 100% of the Brazil business at 7.5x its fiscal year net income. For example, if the put/call were exercised in 2027, the referenced net income would be fiscal year 2026. SGH would receive 19% of such value at, and subject to, the exercise of the put or call. The transaction is expected to close by the end of calendar year 2023, subject to required regulatory approvals and satisfaction of customary closing conditions. SGH expects this transaction to be accretive to its non-GAAP gross margins immediately post-closing; for reference, sales for SMART Brazil were approximately $114M for the first half of SGH's fiscal 2023. In connection with the transaction, SGH expects to recognize a number of one-time items, including transaction-related costs as well as a non-cash charge to operations for the accumulated translation adjustment balance related to the deconsolidation of the operations of SMART Brazil

07:09 EDT Alkermes issues shareholder letter recommending board nominees - Alkermes issued a letter to its shareholders in connection with the company's upcoming 2023 Annual General Meeting of Shareholders to be held on June 29. The letter details the qualifications and experience of the company's board of directors, including the seven directors nominated by the Board for re-election at the Annual Meeting. Highlights of the letter include: since the announcement of Alkermes' Value Enhancement Plan in December 2020, the board has taken action to realign the company's priorities, refine its strategic and operational focus, and effect governance changes. These actions have translated to a share price increase of 49% and outperformance as compared to its peers by 61%, the XBI biotech index by 83% and the NBI biotech index by 56%. The Alkermes directors that Sarissa Capital is seeking to replace possess a mix of broad-based medical, R&D, operational and strategic skills and experiences. The Board does not believe any of the three director candidates proposed by Sarissa would bring additive skills to the Board. The Board came to this conclusion following an engagement with Sarissa that included meetings between Sarissa and independent directors of the Board and the Board's Nominating and Corporate Governance Committee interviewing each of the Sarissa nominees. The Board recommends that shareholders vote "for" all seven of the Board's director nominees.

07:07 EDT SpringBig launches Subscription Loyalty Service - springbig announced the launch of its Subscription Loyalty Service. The service utilizes springbig's catalog of marketing tools to power a retailer's subscriber experience and inspire higher engagement. The company said, "The Subscription Loyalty Service offers retailers complete control to create and manage their paid-subscription programs. Through the Subscription Setup Portal, retailers can dictate subscription rates, implement free trial periods, design subscription tiers and introduce offers for new and returning customers. In addition, retailers can engage with subscribers by offering discounts on reward points and early-bird access to special promotions. The Subscription Loyalty Service enables retailers to segment their consumer base and offer tailored subscription services that personalize the customer experience. At any point, companies can assess the performance of their subscription services by examining analytical dashboards that highlight the most impactful data points."

07:06 EDT Gritstone announces inducement grants under Nasdaq listing rule - Gritstone bio announced that the Compensation Committee of the company's Board of Directors granted five employees nonqualified stock options to purchase an aggregate of 83,300 shares of its common stock with an exercise price of $2.06, which is equal to the closing price of Gritstone's common stock on June 2, 2023, the last trading day preceding the day of the approval. These stock options are part of an inducement material to the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options will vest over a four-year period, with 25% of the options vesting on the first anniversary of the employees' date of hire, and 1/48th of the options vesting monthly thereafter, subject to the employees' continued employment with Gritstone on such vesting dates. The stock options are subject to the terms and conditions of Gritstone's 2021 Employment Inducement Incentive Award Plan and the stock option agreement covering the grant.

07:05 EDT Tiziana Life Sciences appoints Matthew Davis as COO - Tiziana Life Sciences announced the appointment of Matthew Davis, MD, RPh as its new COO. Davis, who also serves as the Chief Medical Officer, will now take on this additional role to further drive the company's growth and strategic initiatives and will report to Gabriele Cerrone, Executive Chairman, Founder, and interim CEO of Tiziana. As the COO, Dr. Davis will be responsible for overseeing Tiziana Life Sciences' day-to-day operations, including research and development, manufacturing, clinical trials, and commercialization efforts.

07:04 EDT Compugen regains Nasdaq compliance - Compugen announced that on June 12, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market notifying the company that it had regained compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rule 5550(a)(2).

07:02 EDT Prospector Capital, LeddarTech enter business combination agreement - LeddarTech and Prospector Capital announced their entry into a definitive business combination agreement that would result in LeddarTech becoming a publicly listed company. Upon closing of the transaction, which is expected by the fourth quarter of 2023, LeddarTech is expected to be listed on Nasdaq under the ticker symbol "LDTC." The transaction values LeddarTech at a pro-forma equity value of U.S. $348 million and is expected to provide LeddarTech with up to U.S. $66 million in gross cash proceeds, which are expected to be used to fund the commercialization of its first embedded software solutions, expand its product offerings and deepen its customer engagements. LeddarTech is a provider of industry-leading low-level sensor fusion and perception software for ADAS and AD. LeddarTech's software solution is both sensor and processor-agnostic and significantly reduces the cost to OEMs and Tier 1-2 automotive suppliers while delivering improved performance and scalability for entry-level to premium ADAS/AD. ADAS and AD is the largest market within automotive software and is expected to grow at an 11% CAGR to U.S. $42 billion by 2030. The company has a strong early-mover advantage with over seven years of experience working on low-level sensor fusion and perception with 150 patents filed covering a broad array of foundational technologies such as signal acquisition, perception and fusion. The transaction has been unanimously approved by the board of directors of Prospector, as well as the board of directors of LeddarTech, and is subject to the satisfaction of customary closing conditions, including the approval of LeddarTech's and Prospector's shareholders and the receipt of a final order of the Superior Court of Justice of Quebec approving the transaction. The combined entity will receive approximately U.S. $23 million from Prospector's trust account, assuming no redemptions by Prospector's public shareholders, as well as U.S. $43 million in gross proceeds from investors including Prospector's sponsor, FS Investors, Investissement Quebec as a representative of the Government of Quebec, Desjardins Capital and BDC Capital participating in the transaction via a convertible private placement investment into LeddarTech.

06:58 EDT TreeHouse provides long-term targets at investor day - TreeHouse will host its 2023 Investor Day and provide a review of the company's strategy. "TreeHouse is a private brand powerhouse in snacking and beverages with a long runway for growth and value creation," said Steve Oakland, Chairman, Chief Executive Officer, and President. "Having repositioned the company, TreeHouse today is a stronger, more focused business, and we are building depth and leadership in high-growth, high-margin categories, while delivering improved execution and consistency. The significant progress our team is making represents our strategy in action, and we could not be more excited by the tremendous opportunity ahead. We are pleased with our start to 2023 and are confident in our ability to achieve our annual growth targets and create value for our shareholders." At today's event, the TreeHouse management team will provide insights into the annual growth targets it has set for 2024 through 2027, including:3%-5% revenue growth, 8%-10% Adjusted EBITDA growth and at least $200M of free cash flow.

06:54 EDT International Game subsidiary awarded 20-year agreement for Brazil lottery - IGT Global Solutions, a subsidiary of International Game Technology and Scientific Games announced that they, along with local partner SAGA Consultoria e Representacoes Comerciais e Empresariais S/A have formed a consortium and executed a concession agreement with the Minas Gerais State Lottery to operate an instants and passive lottery in the State of Minas Gerais, Brazil. Terms of the 20-year agreement provide the consortium with an exclusive license for lottery operations in Minas Gerais, including instant games, a supporting instant ticket system and passive lottery games, with an option in the agreement for a 20-year renewal. IGT and Scientific Games will lead the consortium's operation of the instant ticket and passive lottery business in Minas Gerais, and will jointly provide printed instant games planning and production, while Scientific Games will supply the software and management system requirement.

06:46 EDT Reata Pharmaceuticals names Rajiv Patni, M.D., as Chief R&D Officer - Reata Pharmaceuticals announced the appointment of Rajiv Patni, M.D., as Executive Vice President, and Chief Research & Development Officer. Dr. Patni will report to Warren Huff, CEO, and will be responsible for overseeing the company's research and development functions. Prior to joining Reata, Dr. Patni was Chief Medical Officer at Global Blood Therapeutics from 2020 to 2023.

06:21 EDT Bunge sees Viterra merger accretive to adjusted EPS in first year post close - The combination is expected to generate approximately $250 million of annual gross pre-tax operational synergies within three years of completion. Additionally, the combination is expected to benefit from significant incremental network synergies across joint commercial excellence opportunities, vertical integration efficiencies, and improved logistics optimization and trading optionality from a larger and broader network. The combined company expects to see relatively more stable cash flows from the larger, more diversified footprint. The improvement in the business risk and credit profile of the combined company is expected to drive capital structure efficiencies and cost of capital benefits. The transaction, coupled with the associated $2.0 billion share buyback, is expected to be accretive to Bunge's Adjusted EPS in the first full year post closing and continue to improve with the realization of synergies. The ratings of the combined company at transaction closing are expected to remain strong investment grade, with a pro-forma 2022 adjusted leverage ratio of 1.6x, after factoring in the $2.0 billion share buybacks. The combined company anticipates being able to execute its growth and shareholder plans going forward, while maintaining its current ratings. The transaction is fully funded with a financing commitment of $7.0 billion provided by Sumitomo Mitsui Banking Corporation.

06:16 EDT Bunge to merge with Viterra in a stock and cash transaction

06:02 EDT Interactive Brokers introduces access to Copenhagen and Prague stock exhanges - Interactive Brokers clients worldwide can now trade shares on Nasdaq Copenhagen - CPH - and the Prague Stock Exchange - PSE -. In addition, fractional trading of eligible Nasdaq Copenhagen shares is available. Clients can invest globally in stocks, options, futures, currencies, bonds, funds and more, and fund and trade accounts in up to 26 currencies including the Danish Krone and Czech Koruna.

05:11 EDT ServiceNow plans to create 400 new jobs in Ireland - ServiceNow announced plans to create 400 new jobs in Ireland over the next three years as part of the company's growth plans across Europe, Middle East and Africa, or EMEA. The new roles will be primarily across digital sales, engineering, research and development.

05:08 EDT Western Union, DMW sign MoU to support overseas Filipino workers - Western Union and the Department of Migrant Workers, or DMW, announced that they have signed a Memorandum of Understanding, or MoU, to support the international remittance needs of Overseas Filipino Workers. The MoU bolsters Western Union's relationship with the DMW, while demonstrating its commitment to the country and supporting the financial needs of Filipinos worldwide.

05:00 EDT Charles River launches off-the-shelf lentiviral vector packaging plasmids - Charles River announced the launch of its off-the-shelf lentiviral vector, or LVV, packaging plasmids, providing a streamlined solution to the challenges associated with plasmid sourcing in cell and gene therapies. Cell and gene therapies often rely on plasmid DNA, or pDNA, as a critical starting material. However, production challenges such as capacity bottlenecks and timeline pressures, as well as a need for process development optimization can result in increased lead time, cost and complexity. Charles River's off-the-shelf packaging plasmids offer an alternative solution to these hurdles with immediate availability, reduced development costs and simplified supply chains that streamline and secure lentiviral vector production. In addition to its off-the-shelf offerings, Charles River provides services to meet customer specific needs such as regulatory requirements or product characteristics. These include viral vector production services ranging from clone construction through good manufacturing practice (GMP) for clinical trials or commercial use.